Hence, due to the variability of SF3B1 mutations in solid and hematologic cancers, experiments that query the consequence of the SF3B1 R625 mutation in mucosal melanocytes are needed to understand mis-spliced targets and tumorigenic oncogenic mechanisms related to SF3B1 mutations in MM. This evidence concerns the gene SF3B1 and Miyoshi myopathy.